BioNexus Gene Lab Balance Sheet Health
Financial Health criteria checks 5/6
BioNexus Gene Lab has a total shareholder equity of $9.7M and total debt of $13.2K, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are $11.4M and $1.7M respectively.
Key information
0.1%
Debt to equity ratio
US$13.20k
Debt
Interest coverage ratio | n/a |
Cash | US$5.93m |
Equity | US$9.66m |
Total liabilities | US$1.74m |
Total assets | US$11.40m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: BGLC's short term assets ($8.0M) exceed its short term liabilities ($1.6M).
Long Term Liabilities: BGLC's short term assets ($8.0M) exceed its long term liabilities ($111.0K).
Debt to Equity History and Analysis
Debt Level: BGLC has more cash than its total debt.
Reducing Debt: BGLC's debt to equity ratio has increased from 0% to 0.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BGLC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: BGLC has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 5.2% each year.